Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 3,763 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Type 2 Clear all
Completed Not applicable Interventional

The Effect of a Low-fat Vegan Dietary Intervention on Intracellular Lipid, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes

NCT06106035
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 in Obese
Interventions
low-fat vegan diet
Behavioral
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 14, 2026, 6:41 PM EDT
Recruiting Phase 3 Interventional

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

NCT07662109
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Huntsville, Alabama • Mobile, Alabama • Sheffield, Alabama + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 14, 2026, 6:41 PM EDT
Completed No phase listed Observational Results available

Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes

NCT01494298
View directory record Official record
Conditions
Type 2 Diabetes, African American, Cholesterol, Lipoprotein, Apolipoprotein
Interventions
Not listed
Lead sponsor
Mercer University
Other
Eligibility
18 Years to 79 Years · Male only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 4 Interventional Results available

Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy

NCT01859793
View directory record Official record
Conditions
Diabetes, Atherosclerosis
Interventions
sitagliptin, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 14, 2026, 6:41 PM EDT
Completed No phase listed Observational Results available

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

NCT02197078
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
189,426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Not applicable Interventional

Glutathione-rich Foods for Type 2 Diabetes

NCT04386187
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
GSH Foods, Nutrition education about glutathione sources in the diet, Standard of care nutrition education for type 2 diabetes
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 14, 2026, 6:41 PM EDT
Not listed Not applicable Interventional

The Surgical Treatment of Type 2 Diabetes Mellitus in Non-Morbidly Obese Patients: A Community Hospital Study

NCT01323114
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Laparoscopic duodenal exclusion, Conventional Medical Treatment
Procedure · Other
Lead sponsor
McKenzie Health System
Other
Eligibility
20 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Sandusky, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Not applicable Interventional Results available

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients

NCT02542631
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Bolus Insulin Patch (Calibra Finesse), Insulin Pen (Novo-Nordisk FlexPen®)
Device
Lead sponsor
Calibra Medical, Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Phoenix, Arizona • Escondido, California • Greenbrae, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

NCT01515657
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PL2200 Aspirin Capsules, Immediate-Release Aspirin Tablets, Enteric-coated aspirin caplets
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
21 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Not applicable Interventional

A Brief Intervention to Improve Medication Knowledge and Adherence Among Family Medicine Patients in South Texas

NCT00846300
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hyperlipidemia, Hypertension
Interventions
Physician counseling for health behavior change
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
6
States / cities
Corpus Christi, Texas • Harlingen, Texas • Laredo, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 14, 2026, 6:41 PM EDT
Active, not recruiting Not applicable Interventional

Group Versus Traditional Prenatal Care for Diabetes

NCT03301792
View directory record Official record
Conditions
Pregnancy, Gestational Diabetes, Type 2 Diabetes
Interventions
Group prenatal care
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
St Louis, Missouri • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Aged Garlic Extract (AGE) on Improving Coronary Atherosclerosis in People With Type 2 Diabetes Mellitus

NCT03931434
View directory record Official record
Conditions
Coronary Arteriosclerosis, Endothelial Dysfunction, Type 2 Diabetes Mellitus
Interventions
Aged Garlic Extract (AGE), Placebo
Dietary Supplement
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
30 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 14, 2026, 6:41 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

PRediction Of Glycemic RESponse Study

NCT04881019
View directory record Official record
Conditions
Glycemic Response
Interventions
Continuous glucose monitoring
Device
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
1,070 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

NCT02906930
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
56
States / cities
Lancaster, California • Los Angeles, California • Montclair, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 14, 2026, 6:41 PM EDT
Active, not recruiting Not applicable Interventional

Weight Loss Clinical Decision Support

NCT05198765
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
BMI-CDS
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
10,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 6:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Using Virtual Reality to Improve Medical Training

NCT07542834
View directory record Official record
Conditions
Type 2 Diabetes (T2DM), Geriatric Syndromes, Disability Hearing, Disability Physical, Urinary Tract Infection(UTI), Delirium Confusional State
Interventions
Cinematic Virtual Reality Training, Traditional Didactic Lecture
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 14, 2026, 6:41 PM EDT
Completed No phase listed Observational

Nutritional Therapy for Diabetic Cardiomyopathy

NCT01373814
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
35 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 3 Interventional

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

NCT06269107
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
IcoSema, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Concord, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 14, 2026, 6:41 PM EDT
Recruiting Phase 3 Interventional

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

NCT07684144
View directory record Official record
Conditions
Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions
Maridebart Cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
31
States / cities
Gilbert, Arizona • Canoga Park, California • Cerritos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

NCT02413398
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin 10 mg, Matching Placebo for Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 74 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
27
States / cities
Huntsville, Alabama • Burbank, California • Chula Vista, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 14, 2026, 6:41 PM EDT
Withdrawn Phase 4 Interventional

Effects of Canagliflozin on Intravascular Volume and Hemodynamics

NCT03190798
View directory record Official record
Conditions
Type2 Diabetes Mellitus, Cardiovascular Diseases
Interventions
Canagliflozin 300mg, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 14, 2026, 6:41 PM EDT
Withdrawn Not applicable Interventional

HEART Kitchen Pilot

NCT07037121
View directory record Official record
Conditions
Cardiovascular Diseases, Type 2 Diabetes, Obesity and Obesity-related Medical Conditions
Interventions
Whole Food Plant Based Diet Jumpstart
Behavioral
Lead sponsor
Reya Andrews
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 14, 2026, 6:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise

NCT00795860
View directory record Official record
Conditions
Insulin Resistance and Type 2 Diabetes
Interventions
Weight loss - diet only, Weight loss plus exercise
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 14, 2026, 6:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Circadian Intervention to Improve Cardiometabolic Health

NCT05943626
View directory record Official record
Conditions
Cardiometabolic Syndrome, Type 2 Diabetes, Sleep, Time Restricted Feeding, Lifestyle Factors, Overweight and Obesity, Insulin Sensitivity, Eating Habit, Sleep Hygiene
Interventions
Circadian Intervention
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 14, 2026, 6:41 PM EDT